Emergency: 911 Crisis: call or text 988 PA DDAP: 1-800-662-4357 PA 211: 2-1-1
24/7 Placement Advisors — Call (215) 792-4574

Meth Rehab in Philadelphia, PA | Anchor Point Addiction Center

Overdose deaths involving stimulants but no opioids made up 15% of Philadelphia's overdose deaths in 2023 (Philadelphia Department of Public Health) and 20% in 2024, an 8.6% increase even as total deaths fell (PDPH 2024 report). Stimulants include methamphetamine as well as cocaine.

Why Is Meth a Growing Concern in Philadelphia?

Stimulants, including methamphetamine, are a larger part of Philadelphia's overdose picture than they used to be: stimulant-only deaths rose in 2024 even as overall deaths fell, and opioids and stimulants were found together in half of the city's 2024 overdose deaths (PDPH 2024 report). Many Philadelphia meth users also use opioids — meaning fentanyl contamination of the stimulant supply creates serious overdose risk even for those who do not consider themselves opioid users.

What Does Meth Rehab Look Like?

There is no FDA-approved medication for stimulant use disorder, including methamphetamine use disorder (FDA, 2023). Treatment is primarily behavioral: cognitive behavioral therapy (CBT), contingency management (which has strong evidence for stimulant use disorder), motivational enhancement therapy, and relapse prevention. Inpatient treatment provides the structure, removal from using environment, and peer support that outpatient cannot match — particularly important in early recovery when meth withdrawal (severe fatigue, depression, anhedonia, intense cravings) is at its peak.

What Are Meth Withdrawal Symptoms?

Meth withdrawal is not medically dangerous in the way alcohol or benzodiazepine withdrawal can be — there are no seizure risks. However, the post-use 'crash' is severe: profound fatigue, depression, anhedonia (inability to feel pleasure), hyperphagia (intense hunger), and psychiatric symptoms including paranoia or psychosis in heavier users. These symptoms drive early relapse. Inpatient structure provides critical support through the early period when cravings and depression are at their worst.

Dual Diagnosis and Meth

Co-occurring mental health conditions are particularly common in meth use disorder — ADHD, depression, bipolar disorder, and psychotic-spectrum conditions frequently coexist. Integrated dual diagnosis treatment addresses both the stimulant use disorder and the underlying mental health condition simultaneously, which produces significantly better outcomes than sequential treatment.

Does Insurance Cover Meth Rehab in PA?

Often, yes. Many commercial plans include residential SUD benefits; Pennsylvania's Act 106 sets minimum coverage for alcohol and substance use disorder treatment in group policies (PA Insurance Department). What you pay depends on your plan's deductible and out-of-pocket maximum. Call (215) 792-4574 for a free insurance verification.

Ready to Talk? Call (215) 792-4574 — Available 24/7.

Free insurance verification in minutes. We tell you what your plan covers in one call. Confidential, no obligation.

(215) 792-4574

Frequently Asked Questions

Is there a medication for meth addiction?

No. The FDA has said there is currently no FDA-approved medication for stimulant use disorder (FDA). Treatment is primarily behavioral, with contingency management and CBT showing the strongest evidence. Research on pharmacological treatments continues, but inpatient treatment with evidence-based behavioral therapies and dual diagnosis care remains the clinical standard.

How long does meth withdrawal last?

It varies from person to person. The acute 'crash' brings severe fatigue, depression, and anhedonia, and for some people cravings and mood problems linger well after that. This is one reason a longer inpatient stay is often worth discussing for meth use disorder. A placement advisor can explain what the programs that fit you typically offer.

Call Now